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Verrucous carcinoma of the oral cavity (OVC) is considered a subtype of classical oral squamous cell carcinoma (OSCC). Diag-
nosis is problematic, and additional biomarkers are needed to better stratify patients. To investigate their molecular signature,
we performed low-coverage copy number (CN) sequencing on 57 OVC and exome and RNA sequencing on a subset of these
and compared the data to the same OSCC parameters. CN results showed that OVC lacked any of the classical OSCC patterns
such as gain of 3q and loss of 3p and demonstrated considerably fewer genomic rearrangements compared to the OSCC
cohort. OVC and OSCC samples could be clearly differentiated. Exome sequencing showed that OVC samples lacked mutations
in genes commonly associated with OSCC (TP53, NOTCH1, NOTCH2, CDKN2A and FAT1). RNA sequencing identified genes that
were differentially expressed between the groups. In silico functional analysis showed that the mutated and differentially
expressed genes in OVC samples were involved in cell adhesion and keratinocyte proliferation, while those in the OSCC cohort
were enriched for cell death and apoptosis pathways. This is the largest and most detailed genomic and transcriptomic analy-
sis yet performed on this tumour type, which, as an example of non-metastatic cancer, may shed light on the nature of metas-
tases. These three independent investigations consistently show substantial differences between the cohorts. Taken together,
they lead to the conclusion that OVC is not a subtype of OSCC, but should be classified as a distinct entity.
An aim of the detailed analysis of cancer genomes is to dis-
cover genomic features that are prognostic for disease out-
come and predictive of treatment response. Historically,
genetic changes at specific loci have provided this informa-
tion1 but more recently examination of the whole genome
has been shown to have predictive power. We have illustrated
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the use of whole genome architecture to predict survival in
squamous cell lung carcinoma patients.2 Genomic analysis
has been used to reclassify breast cancer tumours providing
better prediction of disease outcomes3 and recently, molecu-
lar classification using multiple platforms has effectively clus-
tered subtypes across different cancer tissue types, identifying
unexpected associations that could influence choice of
therapy.4
Patients with oral cancer would benefit from a biomarker
that would indicate outcome, specifically regional metastatic
spread. A “wait and see” approach could expose patients to
the risk of under treatment of occult node metastases.
Unnecessary elective neck dissection does have an associated
morbidity and may remove or destroy a natural barrier to
cancer spread. This is of outmost importance when consider-
ing the high risk of developing second primary tumours in
case for oral cancer patients.5
OVC is a case in point. The WHO classification of oral
cancer recognises verrucous carcinomas as a subtype of oral
epithelial cancer.6 It has a different morphological appearance
being exophytic in its growth patterns and a different behav-
iour in that it is not associated with metastatic spread.7 How-
ever, some classical oral squamous carcinomas can have a
verrucous appearance creating diagnostic uncertainty and
subsequent dilemmas of clinical management.8 We ques-
tioned whether genomic profiling could distinguish true ver-
rucous carcinomas from classical squamous carcinomas that
may have a verrucous appearance to produce a useful diag-
nostic biomarker. We used formalin-fixed paraffin-embedded
(FFPE) blocks as a source of tumour DNA for both next-
generation sequencing at low coverage to generate copy num-
ber (CN) profiles,2 and exome sequencing. Additionally,
RNA was isolated from the same blocks and transcription
profiles generated using RNA-seq. Parallel analyses were
undertaken for classical oral squamous cell carcinoma
(OSCC). Comparing the profiles, we found that true verru-
cous carcinomas were easily distinguishable from their classi-
cal counterparts; indeed, no overlap was seen in patterns of
genomic damage and transcriptional profiles could be used to
clearly separate samples into their groups. Unlike classical
oral tumours, TP53 was not inactivated either by mutation or
HPV infection,9 leading us to conclude that verrucous carci-
noma should be considered a separate entity from classical
squamous carcinoma.
Material and Methods
Sample selection
Four different sources of FFPE tissue were used in this study.
Fifteen OVC FFPE blocks were retrieved from the Pathology
Department, St James’s University Hospital, Leeds, UK; 15
OVC FFPE blocks were provided by the Pathology Division,
Queen Victoria Hospital, West Sussex, UK; 40 OVC samples
were provided by the Pathology Division, University of
Torino, Italy and seven OVC FFPE blocks were provided by
the Department of Pathology, National Guard Hospital, Saudi
Arabia. Written informed consent was obtained from all
patients for the use of their tissue in this research and the
study was approved by local ethics committees (REC ref no
07/Q1206/30 and 08/H1306/127). In total, 77 OVC lesions
were identified and all diagnoses were confirmed by the study
pathologist (AH). World Health Organisation (WHO) defini-
tions and criteria were used for the histological diagnosis of
OVC6 (Figs. 1a and 1b). Squamous cell carcinoma lesions
with verrucous appearance were classified as squamous cell
carcinoma with papillary architecture6 (Figs. 1b and 1c). Five
of these samples were analysed by CN sequencing (Fig. 2d),
following which the samples were excluded from further
analysis. For different reasons, such as low yields of the
extracted DNA and failed library preparation, 57 of 77 cases
were suitable for NGS CN analysis, all of which have previ-
ously been shown not to contain human papillomavirus
(HPV) DNA.9 Of these, 12 cases with adequate tissue were
used and successfully prepared for RNA and exome sequenc-
ing. From our ongoing study of head and neck squamous cell
carcinoma (HNSCC),10 we identified 45 HPV-negative OSCC
patients for CN analysis, 16 for RNA-seq and 20 for exome
sequencing. Supporting Information Table 1S summaries the
clinical data from these patients.
DNA isolation for CN analysis
Tissue blocks were cut into sections and epithelial cells of
interest macrodissected as described previously using stained
slides as a guide.9 DNA extraction was performed on macro-
dissected FFPE tissue using Qiagen DNA extraction kits (Qia-
gen, Sussex, UK) according to the manufacturer’s instructions.
DNA concentration and purity were quantified using a Nano-
drop UV spectrophotometer: Nanodrop-8000 (Thermo Scien-
tific, Loughborough, UK). Additionally, double-stranded DNA
What’s new?
Oral verrucous carcinoma (OVC) is considered to be a variant of oral squamous cell carcinoma (OSCC), due mainly to similar-
ities in appearance. However, observed differences in growth patterns and metastatic behavior have raised questions about
their classification. Here, comparisons of genomic data derived from copy number sequencing, exome sequencing, and RNA
sequencing indicate that OVC is distinct from its squamous cell counterpart. In particular, OVCs were characterized by fewer
genomic changes than OSCCs, and the two lacked common driver events. The unique genomic features of OVC warrant its
reclassification within the oral cancer taxonomy.
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concentration was precisely measured using the Quant-iT
PicoGreen dsDNA BR assay (Invitrogen, Paisley, UK).
Nucleic acid isolation for exome and RNA sequencing
DNA and RNA were simultaneously isolated from further
macrodissected tissue from the same patients using the All-
Prep DNA/RNA FFPE kit (Qiagen) according to the manu-
facturer’s instructions. Nucleic acid concentration and purity
were quantified as before. RNA concentration was measured
using The Qubit RNA Assay kit (Invitrogen).
Copy number analysis: library preparation,
sequencing and data analysis
DNA libraries were prepared following two previously
described protocols: for the Illumina Genome analyser GAIIx
sequencer,2 and later, using NEBnext library preparation kits
(New England BioLabs, Hitchin, UK) for the Illumina HiSeq
2500.9 Samples were pooled for cluster amplification and
multiplexed up to 20 samples per lane for Illumina Genome
analyser GAIIx single-end sequencing, and up to 40 samples
per lane and paired-end sequenced (2X100 bp) on an Illu-
mina HiSeq 2500.
Sample reads were split into separate files according to
tags and aligned to the human reference genome. A control
sample was pooled from a group of 20 British normal indi-
viduals downloaded from the 1000 Genomes Project.11 Reads
were trimmed of adaptors using cutadapt,12 aligned to the
human genome (hg19) using BWA.13 Genomic CN was ana-
lysed using CNAnorm.14 The genome was split into 400 kb
Figure 1. Photomicrographs of oral SCC with papillary architecture (a and b) and OVC (c–f). (a) H&E stain of oral SCC with papillary architec-
ture at low power (magnification:  325), but with cytological atypia and invasion present (b) seen at magnification:  3100. (c) H&E
stain showing OVC classical features at low power (magnification:  340) and without cytological atypia or invasion (d) seen at magnifica-
tion:  3100, (e) magnification:  3200 and (f) magnification:  3250.
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windows, and the ratios of tumour and normal read counts
per window were counted and normalised.
Cumulative frequency karyograms were constructed for
the OVC and OSCC cohorts by counting how many samples
had gain and loss for each position along the genome. The
CN profiles of OVC and OSCC were also categorised using
GISTIC2,15 identifying genes within CN-altered regions, and
generating segmented CN heat maps.
The ability to distinguish OVC and OSCC samples using
their CN profiles was also tested using a novel logistic regres-
sion technique.16 Each sample was removed from the total
data set in turn. The remaining samples were then used to
build a predictive model. Each genomic window was given a
score based on its ability to distinguish the two groups. The
model was then applied to the test sample and a subtype pre-
diction was made. This process was repeated for each sample,
with the model being retrained on all other samples each
time, so that no sample was predicted based on a training set
of which it was a part.
Exome sequencing: library preparation, sequencing and
data analysis
DNA sequencing libraries were separately prepared using the
NEBNext singleplex library preparation kit (New England
BioLabs) and then exome DNA was captured with Agilent
exome capture kit (Agilent Technologies, Stockport, UK).
Briefly, 750 ng of each library was hybridized for target
enrichment, followed by washing, indexing and ten-cycle
PCR amplification. Indexed samples were pooled up to four
samples per lane and paired-end sequenced (2X100 bp) on
an Illumina HiSeq 2500. Sequencing was performed to an
average of 903 coverage. Reads were trimmed using cuta-
dapt12 to aligned to the human genome (hg19) using BWA.13
PCR duplicates were removed using Picard (http://picard.
sourceforge.net), and indel realignment and quality score cali-
bration were performed using GATK.17 Variant calling was
performed by Varscan2 in somatic mode,18 and variant con-
sequences were then predicted using the Variant Effect Pre-
dictor.19 Variants were filtered using a number of criteria to
enrich the mutation list for functionally important genes:
Mutations had to pass a Varscan2 Phred somatic score of
threshold of 15 (p values <0.05); mutations had to be present
in more than 50% of tumour cells, calculated taking into
account tumour cell percentages and local CN, as well as
absent in the matched normal sample; mutations that have a
predicted possible consequence on protein function (deleteri-
ous, splice variant, probably deleterious, possibly deleterious,
stop gained).
The DAVID (Database for Annotation, Visualisation and
Integrated Discovery) Bioinformatics Database 6.7 was used to
produce lists of significantly enriched pathways from the
mutated genes passing filters in the OVC and OSCC cohorts.20
RNA-seq: library preparation, sequencing and data
analysis
cDNA libraries were generated from the total RNA using
ScriptSeq complete gold low input kit (Epicenter Biotechnol-
ogies, Madison, WI, USA). All libraries were constructed
according to the manufacturer’s instructions and Ribo-Zero
reagents were used to remove 99% of rRNA (Supporting
Information Table 4S).
Libraries were sequenced to an equivalence of six samples
per lane of a HiSeq2500. Fastq files were processed using
trim_galore to remove low-quality bases, trim adaptors and
fix paired-end reads. Processed reads were aligned to the
human genome GRCh37.p11 by Tophat2.0.7, using the
Figure 2. Examples of the genomic profiles (karyograms) of (a) histologically normal oral epithelium (a patient with an ulcerative lesion),
(b) OVC, (c) OSCC, (d) OSCC with papillary architecture. Each data point represents one window of 400 reads. Genomic position is on the
x-axis and tumour:normal ratio is on the y-axis. The black lines are regions of common copy number between breakpoints. Windows of gain
and loss are red and blue, respectively. Purple and orange arrows, respectively, point to chromosomal gains and losses common to that
tumour type.
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gencode.v17 genome annotation as a guide. Reads could align
a maximum of five times, with two mismatches.
Alignment statistics (Supporting Information Table 4S)
were ascertained using the samtools flagstat command and
CollectRnaSeqMetrics program in the Picard software suite,
version 1.56. Expression quantification and differential expres-
sion analysis (FDR of 0.01) were performed using cuffdiff, ver-
sion 2.1.1, with multireads assigned using the –u parameter.
Principal component analysis (PCA) was performed for all
expressed protein-coding genes in OVC and OSCC samples,
using the prcomp function in R.
The DAVID Bioinformatics Database 6.7 web server was
used to assess the functional enrichment of the significant dif-
ferentially expressed genes (DEGs) between OVC and OSCC.20
Results
DNA CN analysis of OVC versus OSCC
Between 1 and 10 million reads per sample were generated for
CN analysis, equating to one read to every 300 bp–3 kb, or
0.0333–0.333 coverage. CN karyograms were constructed
from 57 OVC and 45 OSCC cases using CNAnorm.14 Individ-
ual karyograms representative of normal epithelium, OVC,
OSCC and OSCC with verrucous architecture are shown in Fig-
ure 2. In general, visual inspection of OSCC karyograms showed
more whole chromosome and localized gain and loss and a
higher degree of aneuploidy across the whole genome when
compared to OVCs. Cumulative frequency karyograms and
GISTIC heatmaps for each tumour type are shown in Figure 3.
OSCC and indeed SCC from other sites have characteristic
genomic features such as gains in chromosomal arms 3q, 5p,
7p, 8q and 20p, and losses in 3p, 4p, 8p and 18q.21,22 All
these chromosomal abnormalities were seen in our OSCC
tumours but none was detected in the OVC group. However,
OVC has its own characteristic features, namely: gains of
7q11.2, 7q22, 3p21, 15q15, 16q22 and 17q23. Chromosomal
losses were infrequent in OVC but detected at 6p21 and
17q12. Samples of OSCC with verrucous architecture all
showed karyograms consistent with classical OSCC.
Visual inspection of individual and cumulative karyo-
grams indicated that there was a substantial difference
between the CN landscape of OVC and OSCC genomes. We
tested this by applying a novel logistic regression method
that blindly predicts the subtype of an “unknown” sample
based on the CN of two groups of “known” samples. Of the
45 OSCC samples, four were misclassified, whereas only one
of 57 OVC samples was incorrectly predicted.
Mutation detection in OVC compared to OSCC
Exome sequencing data were produced from the tumours and
matched adjacent normal epithelium for 12 OVC and 20
OSCC patients. Two OVC patients were excluded owing to evi-
dence of severe DNA damage resulting from tissue fixation, i.e.,
low coverage, high mismatch rate and disproportionally high
ratio of C/T mismatches. The remaining patients’ tumour
DNAs were sequenced to an average of 903 coverage.
From the 12 OVC patients, a total of 224 somatically
mutated genes passed filters, ranging from between 9 (V-123-
01) and 53 (V-116-01) genes per patient. OVC patients’ individ-
ual mutation profiles are listed in Supporting Information Table
2S. From the 20 OSCC patients, 1347 mutated genes passed fil-
ters, ranging from 32 (PG-105) to 143 (PG-144) per patient.
For both tumour cohorts the most frequently occurring
mutations are listed in Table 1. The top five genes (TP53,
CDKN2A, NOTCH1, NOTCH2 and FAT1) in the OSCC cohort
have previously been identified as significant HNSCC cancer
genes.23,24 None of these genes was found to be mutated in the
OVC cohort. However, four genes (DSPP, MUC4, NEFH and
ANP32E) were mutated in the verrucous cohort with a fre-
quency >30% (Table 1 and Supporting Information Table 2S).
These genes were not unique to OVC, being also detected at
lower frequencies in our OSCC cohort (Table 1) although not
detected in other HNSCC exome studies.23,24
For verrucous carcinoma, no genes were mutated in more
than 50% of patients. Nonetheless, the use of DAVID func-
tional analysis revealed involvement of significant number of
OVC-mutated genes involved in cell adhesion and keratino-
cyte proliferation (Supporting Information Table 3S), while
mutated genes in the OSCC cohort were more involved in
cell death and apoptosis pathways (Supporting Information
Table 3S).
Gene expression in OVC compared to OSCC
Gene transcription profiles were generated using RNA-Seq
for all 12 OVC, with an average of 51412094 reads (ranging
from 25602577 to 569763697), and with a median of 82%
mapped reads. Ribosomal RNA ranged between 0 and 0.1%
of the total reads (Supporting Information Table 4S). Gene
expression was quantified as FPKM (fragments per kilobase
per million mapped) for each protein-coding and non-coding
gene. The threshold of 0.1 FPKM was used to determine
whether a gene was expressed. Gene transcription data were
similarly obtained from 16 OSCC samples. Significant differ-
ential expression lists for protein-coding genes in oral verru-
cous samples versus OSCCs are illustrated in Table 2.
The use of DAVID functional analysis revealed that signif-
icant differentially upregulated genes in OVC versus OSCC
are involved in keratinocyte differentiation and epithelium
development (Supporting Information Table 5S), while the
significant differentially upregulated genes in OSCC versus
OVC were more involved in cell growth and migration and
angiogenesis (Supporting Information Table 5S). PCA of all
expressed protein-coding genes in OVC and OSCC revealed
an evident separation of the two cohorts (Fig. 4).
Comparing genomic changes and expression levels
The CN and expression levels of all significantly DEGs were
correlated. Most genes showed no link between expression
and CN. Only three genes, SERPINE1, CDH3 and PLA2G4D,
were both significantly overexpressed in OVC samples and
found in recurrent regions of gain.
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Only one gene reported as mutated in the exome data was
significantly differentially expressed. A missense variant in
CXCL5 was reported in one OVC sample. This gene was
under-expressed in OVC samples compared to OSCC.
Discussion
Clinically, OVC appear as exophytic masses with a verrucous
surface but, less often, they may be relatively smooth. Fur-
thermore, OSCC can have a superficial verrucous appearance,
Figure 3. Frequency of genomic gain and loss for OVC (a) and OSCC (b). Genomic position is on the x-axis, frequency (%) of gains (red) and
losses (blue) are shown on the y-axis. Heat map images of OVC (c) and OSCC (d) based on total segmented DNA copy number variation
profiles. Heat map images were analysed using (GISTIC2.0). In each heat map, the samples are arranged from left to right, and chromo-
somes are arranged vertically from top to bottom. Red represents CN gain and blue represents CN loss.
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thus morphological features alone can lead to misclassifica-
tion with consequences for patient management that may
include unnecessary neck dissections.25 For this reason, new
approaches are needed. Recognising that genomic changes
drive tumour development, we reasoned that verrucous carci-
noma with its more indolent natural history would have a
simpler genotype compared to the more aggressive classical
oral squamous cell tumours. In fact, this had already been
demonstrated superficially by flow cytometry studies26: our
intention was to define these genomic changes more pre-
cisely, providing information that could be developed for
diagnostic biomarkers. Previously, we showed that whole
genome sequencing at low coverage could reveal differences
in HPV-positive and -negative head and neck cancers10 and
therefore we applied this approach, creating karyograms to
compare OVC and OSCC. Additionally, we included exome
sequencing and RNA-seq in our comparative analysis to pro-
vide further precision in defining genomic regions that distin-
guished the two oral cancer subtypes. This study represents
the largest and “first” study, to date, to inspect genomic CN
patterns, somatic gene mutations and transcriptional changes
that occur in OVC and compare them with the CN, muta-
tional and transcriptional events found in OSCC. All earlier
studies on OVC were either case reports or immunohisto-
chemistry studies.
The rarity of these lesions makes them difficult to investi-
gate and previous immunohistochemistry studies on oral ver-
rucous lesions have yielded mixed results.27,28 Variations in
samples, sample numbers, staining procedures and analysis
methods, along with difficulties in defining “gold-standard”
histological criteria for diagnosis, may explain the lack of
concordance between these studies.
Consistent with the analyses by flow cytometry,26 visual
examination of the 57 OVC CN traces revealed a lower level
of genomic damage when compared with 45 OSCC samples.
This suggests that OVC is characterised by a lower degree of
chromosomal instability than OSCC. This lower level of
chromosomal instability could be linked to the minimal or
absent histological cytological atypia found in OVC.29 We
used logistic regression analysis to obtain statistical quantita-
tion of the CN differences, correctly identifying 56 of 57
OVC samples and 41 of 45 OSCCs.
Interestingly, losses were detected frequently in OSCC
genomes but rarely in OVCs. Losses on chromosomal arms
3p, 4q, 9p and 18q, and gains on 3q, 5q, 8q and 20p are
chromosomal signatures commonly linked with OSCCs21,22
and were frequently identified in this OSCC cohort but were
absent in OVC, suggesting that these CN alterations may be
related to the more aggressive behaviour of OSCC. However,
OVC karyograms revealed their own distinctive features that
were consistent for the subtype, namely gains at 7q11.2, 7q22
and 17q23, as well as loss at 17q12 at a frequency of 50%.
These changes have not been previously identified as com-
mon CN altered chromosome lesions in oral cancer.
Comparison of the mutation profiles of the two subgroups
provided further evidence that they had distinguishable geno-
types. Four genes are mutated in more than one OVC sam-
ple, suggesting that they may have a role in the development
of OVC lesions. These genes are: DSPP gene (mutated in
40% of OVC cohort), MUC4, NEFH and ANP32E (mutated
in 30% of OVC cohort). These four genes are also mutated
in at least one OSCC sample and have all been seen in other
cancers. Earlier studies reported upregulation of DSPP along
with other genes in histologically aggressive and poorly dif-
ferentiated OSCC and in some oral epithelial dysplasia.30
Other studies have demonstrated a positive correlation
between MUC4 expression and tumour growth and malig-
nant progression in pancreatic lesions.31 NEFH was downre-
gulated along with other genes in metastatic lung squamous
cell carcinoma samples when compared with non-metastatic
samples.32 ANP32E expression was upregulated in gastric
cancer cells when compared with non-neoplastic epithelial
cells.33 All three OVC samples with an ANP32E mutation
had missense mutations in exactly the same position, which
makes this gene a strong candidate for a role in the develop-
ment of oral verrucous tumours. ANP32E has a variant that
has been reported to be associated with breast cancer devel-
opment.34 Two of the four samples showing DSPP mutations
exhibited identical in-frame deletions, as did two of the three
were NEFH mutations.
Interestingly, analysis of the exome data for all ten OVC
samples showed no mutations within the TP53, CDKN2A,
NOTCH1, NOTCH2 and FAT1 genes, all of which were fre-
quently mutated in OSCC samples in this study and previ-
ously published work.23,24 In particular, mutation of the
tumour suppressor, TP53 gene, is among the earliest identi-
fied genetic changes and the most common in HNSCC, aris-
ing in over half of all cases.35 No mutations were found in
any of the ten OVC samples. The most recent gene expres-
sion study compared six patients with primary OSCC and
five patients with primary OVC using microarray technol-
ogy.36 Of the 167 DEGs reported, 39 were shared between
OSCC and OVC, and eight (HLF, TGFBI, SERPINE1, MMP1,
INHBA, COL4A2, COL4A1 and ADAMTS12) were
Table 1. Frequently occurring mutations in OVC and OSCC cohorts
Genes
Mutated
in OSCC Percentage
Mutated
in OVC Percentage
TP53 Yes 70 No
CDKN2A Yes 35 No
NOTCH1 Yes 10 No
NOTCH2 Yes 25 No
FAT1 Yes 20 No
DSPP Yes 5 Yes 40
MUC4 Yes 15 Yes 30
NEFH Yes 20 Yes 30
ANP32E Yes 5 Yes 30
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Table 2. Significant differential expression list for protein-coding genes in oral verrucous samples versus OSCCs
Gene name Gene function Log FC P.adj
UNC45B Myoblast fusion 5.73176541 1.02E209
ANKRD30BL – 5.068125637 3.00E209
KRT2 Keratin gene, involved in differentiation 3.28887873 4.25E207
DLG2 Guanylate kinase 3.142861272 3.25E206
RP11-181C3.1 – 2.589914427 4.46E206
KRT76 Keratin gene, structural integrity of epithelial cells 4.393647354 4.37E205
LOR Keratinocyte cell envelope protein 3.696791035 0.000182642
ELOVL4 Elongates fatty acids 1.913915467 0.000341653
HTRA3 Probable serine protease 21.624779995 0.000341653
PDK4 Glucose metabolism 22.442699908 0.000497839
FLG2 Filaggrin family 4.155257725 0.000682528
MT2A Binds heavy metals 22.067002668 0.000737808
HPGD Prostoglandin inactivation. Inhibits proliferation in colon cancer 1.75292207 0.00078544
TNFRSF12A Induces apoptosis, promotes angiogenesis,
may modulate cell adhesion to matrix proteins
21.923891955 0.000790342
IGFBP6 Affects growth-promoting effects of insulin-like growth factors 22.386076713 0.000966215
ATP10B – 1.718836376 0.001069055
HBB Affects blood pressure 3.554687453 0.001114319
SLC11A1 Iron metabolism, pathogen resistance 21.677099745 0.001188788
FDCSP Binds to surface of B-lymphoma cells 3.705508687 0.001313018
FSTL3 Bone formation, differentiation of haemopoietic progenitor cells 21.641022383 0.001395803
PTGDR2 Prostaglandin receptor 2.991133602 0.001395803
DSC1 Keratinisation of epithelial tissue 2.515586707 0.001634268
TCAP Muscle assembly 24.437644385 0.001634268
DDIT4 Promotes neuronal cell death 22.274816537 0.002274577
INPP5F Decreases AKT and GSK3B phosphorylation 2.093068765 0.002500484
PID1 – 1.742685358 0.002934709
ENTPD3 ATD/ADP hydrolysis 1.037851739 0.002934709
PLA2G4D Inflammation 2.117301287 0.003105351
CTC-236F12.4 – 1.109388981 0.003105351
PDLIM3 Actin organisation 22.03957167 0.003434804
C10orf53 – 2.290929173 0.004033844
THBS1 Cell–cell and cell–matrix interactions 22.189567433 0.005454379
CXCL5 Neutrophil activation 22.570674984 0.006168571
SERPINH1 Collagen binding 21.43209521 0.007136242
MT1X Binds heavy metals 21.54913047 0.007136242
WNT9A Probable developmental protein 21.802040084 0.007747887
LCE1A Precursor of stratum corneum 2.964477071 0.008599762
LAMC2 Migration, attachment and organisation of cells in embryonic development 22.28993045 0.008730485
CYC1 Mitochondrial activity 21.369128527 0.008958146
SMR3B Androgen-regulated protein 23.661364151 0.009270752
HLF Member of PAR family 1.349932377 0.009352683
CTGF Cell proliferation, differentiation and adhesion 21.972202278 0.009409324
Log FC refers to the log of the fold change. P.adj is the adjusted p-value. Positive log fold change indicates genes overexpressed in OVC, while nega-
tive values indicate genes overexpressed in OSCC.
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significantly differentially expressed between the two groups.
Seven of the eight were upregulated in OSCC compared to
OVC, with only HLF being comparatively upregulated in
OVC. For all eight significantly DEGs between the two
groups previously reported, similar significant expression
changes were observed for in our study, with HLF being the
only gene from that previous list significantly upregulated in
OVC compared to OSCC. HLF is thought to be tumour sup-
pressor gene that plays a role in the detoxification
processes.37
Several of the genes differentially expressed between the
two groups offer plausible explanations for the relatively
benign nature of OVC lesions, and their correspondingly low
metastatic potential, when compared to classical OSCC.
The TNFRSF12A, IGFBP6, FSTL3, SMR3B and LAMC2
protein-coding genes have previously been reported as highly
expressed in head and neck cancer.38–43 These were overex-
pressed in the OSCC cohort compared to the OVC samples.
In contrast, downregulation of the DLG2, HBB and DSC1
genes has been associated with progression.44–46 These all
were expressed more highly in the OVC samples. Similarly,
KRT76 and KRT2 have been reported to be downregulated in
OSCC47 and were again more highly expressed in our OVC
samples.
Amongst genes associated with metastasis, downregulation
of HPGD has been shown to be a marker for metastasis.48
This gene is more highly expressed in the OVC cohort. In
contrast, overexpression of CXCL5, THBS1, MT2A and
MT1X has been linked to metastasis.49–51 All of these genes
were more highly expressed in the OSCC cohort.
DAVID functional enrichment and pathway analysis on
RNA and exome sequencing OVC data revealed that a signif-
icant number of the DEGs and mutated genes are located in
the plasma membrane, participated in cell adhesions and
keratinocyte differentiation and implemented in calcium ion
(Ca21) binding. On the other hand, the OSCC data revealed
that the majority of the upregulated and mutated genes
located in the cytoskeleton, participated in cell adhesion and
migration, angiogenesis and cell death and were implemented
in nucleotide and growth factor binding.
We have undertaken to better define the genomic and
transcriptomic changes associated with oral verrucous carci-
noma, and compare them to the changes observed in a simi-
lar group of classical OSCCs. We used the three independent,
complementary techniques of CN sequencing, exome
sequencing and RNA sequencing. For all three methods,
there were clear differences that distinguish the OVC and
OSCC cohorts. Taken together, these three independent anal-
yses offer persuasive evidence that OVC should not be classi-
fied as a subtype of OSCC, but should be considered a
separate disease entity.
Using a number of genomic platforms, it has recently
been shown that tumours are not always closely related by
tissue of origin.4 We have shown here that this applies to
these two tumours, verrucous and squamous, both arising in
the oral cavity. Verrucous carcinoma although rarely meta-
static can be locally destructive and invasive and may benefit
from therapeutic approaches in addition to surgery. The
genomic and transcriptomic changes described here may sug-
gest routes to the identification of a drug target, specific for
these verrucous tumours. It would be of interest to determine
if verrucous carcinomas that occur at other tissue sites share
the same molecular signatures as those we have described for
the oral cavity and possibly grouped together for the identifi-
cation of treatment targets.
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